Trial reportPediatric blood & cancer2009
Treatment of children with acute promyelocytic leukemia: results of the first North American Intergroup trial INT0129.
Trial report in Pediatric blood & cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- The role of maintenance therapy in acute promyelocytic leukemia in the first complete remission.The Cochrane database of systematic reviews · 2013Pooled it
- Outcome for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance).Pediatric blood & cancer · 2019Trial
- Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2017Trial
- Effects of Anionic Liposome Delivery of All-Biomimetics (Basel, Switzerland) · 2024Article
- Retinoid Therapy for Neuroblastoma: Historical Overview, Regulatory Challenges, and Prospects.Cancers · 2024Review
- Children's Oncology Group's 2023 blueprint for research: Myeloid neoplasms.Pediatric blood & cancer · 2023Article
- Article
- Chemotherapy-free treatment for acute promyelocytic leukemia: the pediatric view of a revolutionary tale.Frontiers in oncology · 2023Review
- Review
- Acute Promyelocytic Leukemia in Children: A Model of Precision Medicine and Chemotherapy-Free Therapy.International journal of molecular sciences · 2021Review
- Article
- Same sibling marrow following cord allogeneic transplantation as therapy for second relapse acute promyelocytic leukemia in a pediatric patient.Pediatric transplantation · 2016Article
- Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2015Review
- Inching toward cure of acute myeloid leukemia: a summary of the progress made in the last 50 years.Medical oncology (Northwood, London, England) · 2014Review
- Acute Promyelocytic Leukemia (APL): Comparison Between Children and Adults.Mediterranean journal of hematology and infectious diseases · 2014Review
- How I treat children and adolescents with acute promyelocytic leukaemia.British journal of haematology · 2014Review
- Retrospective analysis of 119 cases of pediatric acute promyelocytic leukemia: Comparisons of four treatment regimes.Experimental and therapeutic medicine · 2012Article
- Lessons from the past: opportunities to improve childhood cancer survivor care through outcomes investigations of historical therapeutic approaches for pediatric hematological malignancies.Pediatric blood & cancer · 2012Review
- Recent advances in the diagnosis and management of childhood acute promyelocytic leukemia.Korean journal of pediatrics · 2011Article
- Biology, risk stratification, and therapy of pediatric acute leukemias: an update.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 12 institutions in 3 countries.
Funding
Abstract
backgroundThis report focuses on the children enrolled on the first North American Intergroup study of APL (INT0129). This study was designed to compare the rates of CR, disease-free survival (DFS), overall survival (OS) and toxicity of therapy with all-trans-retinoic acid (ATRA) for remission induction and/or maintenance compared to conventional chemotherapy in patients with previously untreated APL. PROCEDURE: Fifty-three patients who were documented to have the t(15;17) translocation were able to be evaluated for toxicity of treatment, outcome of induction, and survival.
resultsThe overall CR rate was 81%. The estimated 5-year DFS from time of CR was 41% for all patients. The estimated 5-year OS for all patients from entry into the study was 69%. The 5-year DFS from time of CR for patients who were randomized to ATRA for induction or maintenance or both was 48% compared to 0% for patients who never received ATRA (P < 0.0001).
conclusionsThe most important finding of our study is that a significant DFS advantage exists for children with APL who received ATRA during induction or maintenance or both compared to children who received no ATRA. Furthermore, remissions in these children appear durable as the OS rates are stable at 10 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.